Drugs / Rhodiola

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT02242461 May 2012 → Jul 2013 chronic obstructive pulmonary disease Chung Shan Medical University Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04218916 Jan 2020 → Jan 2021 coronary microvascular disorder Qilu Hospital of Shandong University Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT01098318 Jun 2010 → Jul 2013 depressive disorder University of Pennsylvania Completed No outcome recorded
Phase 42 trials
Phase 4 NCT02737020 Apr 2016 → Mar 2021 attention deficit-hyperactivity disorder Hospital de Clinicas de Porto Alegre Unknown No outcome recorded
Phase 4 NCT02737033 Apr 2016 → Mar 2021 attention deficit-hyperactivity disorder Hospital de Clinicas de Porto Alegre Unknown No outcome recorded
Phase not applicable1 trial
NCT06889584 Feb → Dec 2025 University of South Carolina Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01536288 Comparator Oct 2010 → May 2011 acute mountain sickness Chang Gung Memorial Hospital Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Rhodiola ClinicalTrials.gov intervention name — accepted as the source's own label NCT02737020
1

NCT02737033

Known as Rhodiola crenulata ClinicalTrials.gov intervention name — accepted as the source's own label NCT01536288
1

NCT02242461

Known as Rhodiola rosea “Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy.” NCT01098318
2

NCT06889584

NCT04218916

Modality Traditional medicine (herbal / TCM) “R. rosea belongs to the family Crassulaceae, and has a long history as a folk remedy for enhancing physical and emotional endurance.” NCT01098318